Abstract
Overview
Introduction
Datamonitor expects the antihypertensives market to reach almost $40 billion,
across the seven major markets, by 2016. The growth will be driven by the
uptake of Novartis' s Tekturna, as well as increased use of ARBs, and their
combinations. However, the expiries of some key patents, particularly Pfizer' s
Norvasc and Merck' s Cozaar, will restrain market growth.
Scope
- Event-driven sales forecasts for 2007-16 across the seven major markets:
US, France, Germany, Italy, Spain, UK and Japan.
- Country and market specific issues that will impact sales opportunities
and market landscape, including key patent expiries and product launches.
- Case studies assessing the blockbuster potential of Novartis' s direct
renin inhibitor, Tekturna, and the impact of ESC/ESH guideline reform in
Europe.
- Comprehensive analysis of the current antihypertensives pipeline,
including a clinical and commercial assessment of all key emerging therapies.
Highlights
The growth rate of the antihypertensive market is declining. The market is
mature and does not present an attractive opportunity for R&D expenditure;
consequently Big Pharma are shying away from the pursuit of novel mechanisms
of action in favour of developing more efficacious combination therapies.
Cozaar' s patent expiry in the US, has the potential to alter the structure of
the antihypertensive market dramatically. Threats of generic substitution and
money-saving healthcare strategies which have plagued other markets, are now
approaching the successful ARB class, and will have an impact on the whole
antihypertensive market.
Novartis is set to strengthen its position in the antihypertensives arena;
Tekturna is expected to achieve international blockbuster status and Exforge
will achieve sales of at least $800m, set back slightly by the premature
expiry of Pfizer' s Norvasc patent.
Reasons to Purchase
- Quantify the future size of the antihypertensives market and identify
opportunities for new products.
- Learn how recent European healthcare reforms and guideline updates will
shape the antihypertensives market.
- Understand the barriers to uptake for novel antihypertensive agents, and
the need for paradigm shift in clinical trial design.
| 
View Cart
